title: Intra-arterial injection of iodine-131-labeled lipiodol for treatment of hepatocellular carcinoma.
abstract: OBJECTIVE
  The therapeutic effect of intra-arterial injection of 131-iodine-labeled lipiodol for treatment of hepatocellular carcinoma in palliative or adjuvant settings has been promising. We report, the results of an open study of this therapy in cirrhotic patients with small hepatocellular carcinoma.
  
  
  METHODS
  Forty patients with hepatocellular carcinoma were given intra-arterial injections of 131-iodine-labeled lipiodol. These injections were repeated if necessary every 3 months. Tumor response (WHO criteria) was determined on CT scans performed after each treatment and every 3 months during the follow-up. Side effects and the cause of death were recorded. Therapeutic response and survival were analyzed.
  
  
  RESULTS
  The median number of treatment was 2 (1-4). There was one complete response, 18 partial responses (47.5% response rate); 19 had stable disease and 2 progressions. Overall survival rates (+/-CI 95%) at 1, 2 and 3 years were: 90+/-4.7%, 60.3+/-8%, and 39+/-8.3%, respectively. Median survival was 27 months; 25 patients have died (4-56 months), 8 of tumor progression with a multifocal spread in the liver. Tolerance was good except for 2 patients who develop a fatal drug-related pulmonary insufficiency.
  
  
  CONCLUSIONS
  These data suggest that intra-arterial therapeutic injection of 131-iodine-labeled lipiodol for treatment of hepatocellular carcinoma can provide high rate response and long survival for individuals not eligible for surgery or local treatment.
authors.affiliation: Department of Medical Oncology, Centre Eugène Marquis, Rennes, France. boucher@rennes.fnclcc.fr
authors.forename: Eveline
authors.initials: E
authors.lastname: Boucher
authors.forename: Etienne
authors.initials: E
authors.lastname: Garin
authors.forename: Anne
authors.initials: A
authors.lastname: Guylligomarc'h
authors.forename: Damien
authors.initials: D
authors.lastname: Olivié
authors.forename: Karim
authors.initials: K
authors.lastname: Boudjema
authors.forename: Jean-Luc
authors.initials: JL
authors.lastname: Raoul
mesh_terms: D000368:Aged; D006528:Carcinoma, Hepatocellular / Q000401:mortality / Q000532:radiotherapy*; D003287:Contrast Media / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007269:Injections, Intra-Arterial; D007457:Iodine Radioisotopes / Q000008:administration & dosage; D007459:Iodized Oil / Q000008:administration & dosage / Q000627:therapeutic use*; D008113:Liver Neoplasms / Q000401:mortality / Q000532:radiotherapy*; D008297:Male; D009367:Neoplasm Staging; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D003287:Contrast Media; D007457:Iodine Radioisotopes; D007459:Iodized Oil